Boris Kallmann
YOU?
Author Swipe
View article: REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program Open
Introduction Treatment adherence is a critical success factor in the disease-modifying therapy (DMT) of multiple sclerosis (MS). The REBISTART study prospectively evaluated adherence in patients using components of a patient support progra…
View article: Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 Open
Continuous monitoring of disease activity during the treatment-free period is important. Subsequent management depends on the presence or absence of inflammatory disease activity, determined in the absence of consistent guidelines via prac…
View article: Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status Open
Background and aims: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. Methods: Prespecified analysis of a non-interventional, prospective, real…
View article: Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) Open
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased unders…
View article: Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study Open
Background: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teri…
View article: An epidemiological study on the course of disease and therapeutic considerations in relapsing–remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)
An epidemiological study on the course of disease and therapeutic considerations in relapsing–remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM) Open
Background: In relapsing–remitting multiple sclerosis (RRMS), ‘no evidence of disease activity’ (NEDA) is regarded as a key treatment goal. The increasing number of treatments allows for individualized treatment optimization in patients wi…